Part 6: Results From OptiTROP-Breast02

We are pleased to present Part 6, the final installment of an exclusive podcast series, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer.Part 6 of this series provides peer-to-peer physician perspectives on the results from the OptiTROP-Breast02 trial.Topics include:Results from OptiTROP-Breast02: Sacituzumab tirumotecan (sac-TMT) as a novel TROP2-directed antibody drug conjugate (ADC)Future direction of ADC treatmentsDiscussants:Neil M. Iyengar, MDDirector, Survivorship Services, Winship Cancer Institute of Emory UniversityCo-Director, Breast Medical Oncology, Department of Hematology and Medical OncologyAssociate Professor, Department of Hematology and Medical OncologyEmory University School of MedicineAtlanta, GASeth Wander, MD, PhDDirector, Precision Medicine, Termeer Center for Targeted TherapiesDirector, Translational Research, Breast Oncology ProgramAssistant Professor of Medicine, Harvard Medical SchoolMassachusetts General HospitalBoston, MASponsored by Lilly